J&J-Guidant Merger Spotlights Stent Patent Wars

Law360, New York (November 15, 2005, 12:00 AM EST) -- Johnson & Johnson’s pending $21.5 billion acquisition of Guidant, one of the largest mergers in the history of the medical device industry, puts the spotlight on the intense legal battle over the lucrative patents to drug-coated stents, attorneys say.

J& J and Guidant are active worldwide in vascular medical devices, with their products used to treat diseases within the heart, as well as other parts of the body.

Before the two companies began discussing the merger, they were on opposite sides of the courtroom disputing heart...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.